Our highly experienced equity analysts interview the management teams of emerging companies in some of the most promising sectors, including healthcare and technology.
In the first episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, discusses InMed’s biosynthesis platform and its pipeline of cannabinoids with Eric Adams, InMed’s CEO, and Alexandra Mancini, senior VP of clinical and regulatory affairs. The discussion also includes the recent FDA public hearing on CBD and its implications for the sector.